RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026

RxSight, Inc.

CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.
Consulting agreement provides $15,000 monthly retainers for Jan-Mar 2026, plus $500/hour for services.
Thunen remains eligible for fiscal 2025 annual cash bonus based on corporate performance.
Outstanding stock options continue vesting during consulting term ending Dec 31, 2026.
No successor named; Ron Kurtz cites nearly decade of service; company has 1,100+ LDDs and 250k+ procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.